Hinge Health, Inc. (HNGE)
| Market Cap | 4.33B |
| Revenue (ttm) | 646.34M +49.8% |
| Net Income | -511.39M |
| EPS | -7.27 |
| Shares Out | 77.38M |
| PE Ratio | n/a |
| Forward PE | 20.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,863,082 |
| Open | 55.10 |
| Previous Close | 55.00 |
| Day's Range | 53.97 - 56.02 |
| 52-Week Range | 30.08 - 62.18 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 62.13 (+10.91%) |
| Earnings Date | May 5, 2026 |
About HNGE
Hinge Health, Inc. focuses on building a health system that scales and automates the delivery of care using technology. It designs its platform to address musculoskeletal system care (MSK), including acute injury, chronic pain, and post-surgical rehabilitation. The company also provides personalized and automated MSK care through AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device. It primarily serves self-insured employers. The company was founded in 2012 and is headquartered in San Francisco, C... [Read more]
Financial Performance
In 2025, Hinge Health's revenue was $587.86 million, an increase of 50.58% compared to the previous year's $390.40 million. Losses were -$424.09 million, 3453.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for HNGE stock is "Strong Buy." The 12-month stock price target is $62.13, which is an increase of 10.91% from the latest price.
News
Hinge Health price target raised to $62 from $52 at Barclays
Barclays raised the firm’s price target on Hinge Health (HNGE) to $62 from $52 and keeps an Overweight rating on the shares. The firm says the company’s better Q1 billings
Hinge Health price target raised to $80 from $65 at Citizens
Citizens raised the firm’s price target on Hinge Health (HNGE) to $80 from $65 and keeps an Outperform rating on the shares. Hinge Health is seeing strong momentum with accelerating
Hinge Health price target raised to $67 from $59 at Stifel
Stifel analyst David Grossman raised the firm’s price target on Hinge Health (HNGE) to $67 from $59 and keeps a Buy rating on the shares.
Hinge Health price target raised to $63 from $53 at Canaccord
Canaccord raised the firm’s price target on Hinge Health (HNGE) to $63 from $53 and keeps a Buy rating on the shares. The firm saidtThe revenue upside did not match
Hinge Health price target raised to $65 from $55 at RBC Capital
RBC Capital analyst Rishi Jaluria raised the firm’s price target on Hinge Health (HNGE) to $65 from $55 and keeps an Outperform rating on the shares. The company delivered another
Hinge Health price target raised to $95 from $60 at Piper Sandler
Piper Sandler raised the firm’s price target on Hinge Health (HNGE) to $95 from $60 and keeps an Overweight rating on the shares. The firm notes the company reported extremely
Hinge Health price target raised to $70 from $55 at Raymond James
Raymond James raised the firm’s price target on Hinge Health (HNGE) to $70 from $55 and keeps an Outperform rating on the shares. Hinge Health delivered a strong Q1 beat
Hinge Health price target raised to $70 from $55 at Raymond James
Raymond James analyst Brian Peterson raised the firm’s price target on Hinge Health (HNGE) to $70 from $55 and keeps an Outperform rating on the shares.
Hinge Health price target raised to $79 from $63 at Truist
Truist analyst Jailendra Singh raised the firm’s price target on Hinge Health (HNGE) to $79 from $63 and keeps a Buy rating on the shares. The firm cites the company’s
Hinge Health price target raised to $63 from $59 at Needham
Needham analyst Ryan MacDonald raised the firm’s price target on Hinge Health (HNGE) to $63 from $59 and keeps a Buy rating on the shares. The company reported excellent Q1
Hinge Health Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue and profitability far exceed expectations, driven by strong demand, AI-enabled efficiency, and rapid adoption of new offerings like Migraine Care. Guidance for 2026 was raised significantly, reflecting robust pipeline growth and expanding client base.
Hinge Health reports record first quarter 2026 financial results
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the first quarter ended March 31, 2026. “We generated $182 million in revenue this quarter with 47...
Hinge Health launching migraine treatment program, WSJ reports
Hinge Health (HNGE) is launching a program to treat and prevent migraine headaches, Connor Hart of Wall Steet Journal reports, citing an interview the company’s CEO Daniel Perez. “We started
Hinge Health announces launch of comprehensive Migraine Care program
Hinge Health (HNGE) introduced its Migraine Care Program, offering rapid drug-free pain relief, personalized trigger management, and expert-led prevention for members. With meaningful overlap between ...
Hinge Health launches comprehensive Migraine Care Program
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today introduced its Migraine Care Program, offering rapid drug-free pain relief, personalized trigger management, and expert-led preven...
Hinge Health price target lowered to $45 from $50 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson lowered the firm’s price target on Hinge Health (HNGE) to $45 from $50 and keeps an Outperform rating on the shares. The firm made several
Hinge Health to announce first quarter 2026 financial results on May 5, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) announced today that it will report its financial results for the quarter ended March 31, 2026, after the U.S. financial markets close o...
Hinge Health reports support for over 300 public sector organizations
Hinge Health (HNGE) announced its expansion throughout the public sector, now delivering musculoskeletal care to employees across 24 state employee health plan clients. With MSK conditions continuing ...
Hinge Health now supports over 300 public sector organizations including 24 state governments
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced its expansion throughout the public sector, now delivering musculoskeletal (MSK) care to employees across 24 state emplo...
Hinge Health appoints Tyler Sloat to its board of directors
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced the addition of Tyler Sloat to its board of directors. Sloat currently serves as the Chief Financial Officer and Chief O...
Hinge Health price target raised to $55 from $50 at RBC Capital
RBC Capital analyst Rishi Jaluria raised the firm’s price target on Hinge Health (HNGE) to $55 from $50 and keeps an Outperform rating on the shares after hosting investor meetings
Hinge Health price target lowered to $55 from $70 at KeyBanc
KeyBanc lowered the firm’s price target on Hinge Health (HNGE) to $55 from $70 and keeps an Overweight rating on the shares.
Hinge Health price target lowered to $53 from $65 at Canaccord
Canaccord lowered the firm’s price target on Hinge Health (HNGE) to $53 from $65 and keeps a Buy rating on the shares. The firm said the comopany delivered a strong
Hinge Health Earnings Call Transcript: Q4 2025
Delivered record 2025 results with 51% revenue growth, 31% free cash flow margin, and strong client expansion. Guidance for 2026 projects 25% revenue growth and continued profitability, with investments in AI and Hinge Select positioning for long-term market leadership.
Hinge Health reports Q4 EPS 49c, consensus 43c
Reports Q4 revenue $170.7M, consensus $156.8M. “We closed out the year with an exceptional quarter and a strong selling season, driving our highest win rates to date and greatest number